Cart is empty
View Cart
Subtotal: $0.00
JOIN NOW!
  • ABOUT US
    • Board of Directors
    • Benefits
    • Volunteering
      • Volunteer Opportunities
      • EDEI Committee
      • Education
      • Emerging Leaders
      • Local GAMP CoP
      • Membership
      • Product Show
      • Social
      • Student Development
      • Women in Pharma®
    • Students
      • Student Chapters
      • Career Workshop
      • Scholarships
    • Chapter Awards
      • NEW Chapter Awards 2024
    • Sponsors
    • Contact Us
  • EVENTS
    • Chapter Calendar
    • Educational Programs
    • Social Events
    • Student Activities
    • Product Show
    • Past Events
  • RESOURCES
    • Scholarship Foundation
      • Scholarship Application
    • Podcast
    • Documents
    • Chapter YouTube Channel
    • ISPE Publications
    • ISPE Guidance Documents
    • Member Directory
    • ISPE Training
    • ISPE Communities of Practice
  • BLOG
    • Boston Chapter Blog
      • Contribute
    • ISPE Blog
  • CAREERS
    • Job Board
    • Post a Job
  • Gallery
  • SCHOLARSHIP FOUNDATION
    • About the Foundation
    • Apply for a Scholarship
    • Donate
  • ABOUT US
    • Board of Directors
    • Benefits
    • Volunteering
      • Volunteer Opportunities
      • EDEI Committee
      • Education
      • Emerging Leaders
      • Local GAMP CoP
      • Membership
      • Product Show
      • Social
      • Student Development
      • Women in Pharma®
    • Students
      • Student Chapters
      • Career Workshop
      • Scholarships
    • Chapter Awards
      • NEW Chapter Awards 2024
    • Sponsors
    • Contact Us
  • EVENTS
    • Chapter Calendar
    • Educational Programs
    • Social Events
    • Student Activities
    • Product Show
    • Past Events
  • RESOURCES
    • Scholarship Foundation
      • Scholarship Application
    • Podcast
    • Documents
    • Chapter YouTube Channel
    • ISPE Publications
    • ISPE Guidance Documents
    • Member Directory
    • ISPE Training
    • ISPE Communities of Practice
  • BLOG
    • Boston Chapter Blog
      • Contribute
    • ISPE Blog
  • CAREERS
    • Job Board
    • Post a Job
  • Gallery
  • SCHOLARSHIP FOUNDATION
    • About the Foundation
    • Apply for a Scholarship
    • Donate
RNAi Therapeutic Achieves First-Ever Positive Phase 3 Results

RNAi Therapeutic Achieves First-Ever Positive Phase 3 Results

  • Posted by ISPE Boston
  • On October 19, 2017

Leading RNAi therapeutics company, Alnylam Pharmaceuticals, and Sanofi Genzyme have announced that the Phase 3 study of patisiran met its primary efficacy endpoint and all secondary endpoints. Patisiran is an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy.

“We are very proud to report the first ever positive Phase 3 results for an RNAi therapeutic, marking the potential arrival of an entirely new class of medicines. This moment is the culmination of a 15-year journey of tireless work by countless contributors who have overcome enormous scientific and business challenges to make RNAi therapeutics a reality,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam.

Based on these positive results, Alnylam expects to file its first New Drug Application in late 2017 and first Marketing Authorisation Application shortly thereafter. Sanofi Genzyme is currently preparing for regulatory filings for patisiran in Japan, Brazil and other countries, to begin in the first half of 2018. Pending regulatory approvals, Alnylam will commercialize patisiran in the U.S., Canada and Western Europe, with Sanofi Genzyme commercializing the product in the rest of the world.

Patisiran is an investigational medicine that uses the body’s natural processes to lower the levels of the TTR protein that causes TTR amyloidosis. It is designed to target and silence specific messenger RNA, potentially blocking the production of TTR protein before it is made. This may help to enable the clearance of TTR amyloid deposits in peripheral tissues and potentially restore function to these tissues. The safety and efficacy of patisiran have not been evaluated by the U.S. Food and Drug Administration or any other health authority.

Hereditary transthyretin (TTR)-mediated (hATTR) amyloidosis is an inherited, progressively debilitating, and often fatal disease caused by mutations in the TTR gene. TTR protein is produced primarily in the liver and is normally a carrier of vitamin A. Mutations in TTR cause abnormal amyloid proteins to accumulate and damage body organs and tissue, such as the peripheral nerves and heart, resulting in intractable peripheral sensory neuropathy, autonomic neuropathy, and/or cardiomyopathy. hATTR amyloidosis represents a major unmet medical need with significant morbidity and mortality, affecting approximately 50,000 people worldwide. hATTR amyloidosis patients have a life expectancy of 2.5 to 15 years from symptom onset, and the only approved treatment options are liver transplantation for early stage disease and tafamidis (approved in Europe, Japan and certain countries in Latin America, specific indication varies by region). There is a significant need for novel therapeutics to help treat patients with hATTR amyloidosis. (Source: Alnylam Website, September 20, 2017)

Share this
 
Post Categories
  • Podcasts (1)
  • Industry Buzz (557)
  • Chapter News (536)
  • Knowledge & Training (79)
  • Students & YP (78)
  • Career Tools (13)
Get Updates via Email




Alnylam and Vir Form Alliance to Advance RNAi Therapeutics for Infectious Diseases

CAR T Therapy Scores Another Win as FDA Approves Kite’s Yescarta

Next thumb
Scroll
Follow Us
Search this Site
@2024 ISPE Boston Chapter. All rights reserved.